EXenatide Study of Cardiovascular Event Lowering
Contact us
Phone: +44 (0)1865 857240
Email: dtu@dtu.ox.ac.uk
OVERVIEW
EXSCEL evaluated the cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes.
design
Randomised, placebo-controlled global clinical trial performed in people with type 2 diabetes diabetes, with or without previous cardiovascular disease. In total, 14,752 patients were enrolled between 18th June 2010 and 16th September 2015. EXSCEL was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 687 sites from 35 countries.
RESULTS
The results of EXSCEL were reported at the 2017 meeting of the EASD. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). The corresponding efficacy endpoint analysed for superiority did not reach statistical significance, although a pre-specified analysis suggested all-cause mortality was lower with exenatide compared to placebo. The primary results paper is available here.
Manuscript proposals
The EXSCEL Publications Committee are happy to review proposals for potential new manuscripts. Proposals should be submitted on an EXSCEL Trial Topic Request Form emailed to peter.hoffmann@duke.edu
Joint chairs |
Adrian Hernandez (Previously Robert Califf) |
Sponsor |
Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca |
Funder |
AstraZeneca |
Reference numbers |
EXSCEL PUBLICATIONS
-
Mitochondrial Metabolites Predict Major Adverse Cardiovascular Events in Individuals with Type 2 Diabetes Mellitus
8 September 2023
-
Sex differences in complications, care, and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
1 June 2023
-
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial
1 May 2023
-
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy
16 May 2023
-
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
27 June 2022
-
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial
1 January 2022
-
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial
1 December 2021
-
Predicting Major Adverse Limb Events in Individuals With Type 2 Diabetes: Insights From the EXSCEL Trial
1 October 2021
-
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus
1 September 2021
-
Cardiovascular and renal safety of metformin in patients with diabetes and moderate-to-severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials
1 May 2021
EXSCEL Conference Abstracts
-
Phenotypic features of patients with Type 2 diabetes at increased risk of severe hypoglycemic events occurring before or after cardiovascular events [Diabetes UK Annual Professional Conference]
1 January 2019
-
Patients with diabetes and peripheral arterial disease: Results from the EXSCEL trial [American College of Cardiology (ACC) Annual Scientific Sessions]
1 January 2019
-
Increased risk of severe hypoglycemic events before and after cardiovascular events in type 2 diabetes: Validation of a novel concept [American College of Cardiology (ACC) Annual Scientific Sessions]
1 January 2019
-
Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model [55th Annual Meeting of the European Association for the Study of Diabetes]
1 January 2019
-
Potential impact of differential drop-in of open-label diabetes medications in EXSCEL [54th Annual Meeting of the European Association for the Study of Diabetes]
21 August 2018
-
Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) [54th Annual Meeting of the European Association for the Study of Diabetes]
21 August 2018
-
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial [54th Annual Meeting of the European Association for the Study of Diabetes]
21 August 2018
-
Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) [54th Annual Meeting of the European Association for the Study of Diabetes]
21 August 2018
-
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL [54th Annual Meeting of the European Association for the Study of Diabetes]
21 August 2018
-
Effects of once weekly exenatide on clinical outcomes in the subgroup of patients with preexisting cardiovascular disease: insights from EXSCEL [European Society of Cardiology (ESC) Congress 2018]
1 August 2018
-
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) [American Diabetes Association (ADA) Conference]
1 January 2018
-
EXSCEL-Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus [American Diabetes Association (ADA) Conference]
1 January 2018
-
Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group [American Diabetes Association (ADA) Conference]
1 January 2018
-
Effects of exenatide on cardiovascular outcomes in patients with type 2 diabetes mellitus: results of the EXSCEL study [Diabetes Congress of the German Diabetes Association]
1 January 2018
-
Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: Insights from EXSCEL [14th National Conference of the Primary Care Diabetes Society]
1 January 2018
-
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial [American Heart Association (AHA) Scientific Sessions 2017]
1 January 2017
-
Baseline Characteristics of Patients Enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [American Diabetes Association (ADA) Conference]
1 January 2016